Skip to main content
Clinical Trials/NCT06210711
NCT06210711RecruitingNot Applicable

Prevention of Posttraumatic Stress: A Randomized Controlled Trial of Brief Prolonged Exposure Therapy for Injured Individuals Admitted to a Level I Trauma Center

Baylor Research Institute3 sites in 1 country300 target enrollmentStarted: February 28, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
300
Locations
3
Primary Endpoint
PTSD Checklist for DSM-5 (PCL-5)

Study Overview

Brief Summary

The purpose of this research is to determine if a brief treatment method is effective for preventing posttraumatic stress disorder (PTSD) and a number of other concerns following injury.

Detailed Description

This is a prospective randomized controlled trial examining the efficacy of brief Prolonged Exposure Therapy (Brief PE) delivered to individuals admitted to a Level I Trauma Center to reduce PTSD symptoms. The overall goal of this project is to test a Brief PE (three 60-minute sessions) to reduce psychological distress after injury and to mitigate long-term post-injury distress including PTSD as well as secondary health outcomes (including depression, general anxiety, pain, and quality of life) at 1, 3, and 6 months from baseline. The intervention group (Brief PE) will be compared to standard clinical care with treatment as usual (TAU).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Between the ages of 18 and 75 years old.
  • Admitted to Baylor University Medical Center at Dallas (BUMC), Baylor Scott & White Medical Center at Temple (BSWMC), or Froedtert Hospital and the Medical College of Wisconsin (FH/MCW) Level 1 Trauma Center

Exclusion Criteria

  • Patients in police custody
  • Patients not fluent in English
  • Patients with severe cognitive impairment
  • Patients who are acutely suicidal
  • Patients with active psychosis

Arms & Interventions

Treatment as Usual

Placebo Comparator

Participants in the Treatment as Usual group (TAU) will not receive the Brief PE therapy, but the standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months from Baseline.

Intervention: Treatment as Usual (Behavioral)

Brief Prolonged Exposure

Experimental

Participants in the experimental group will receive Brief Prolonged Exposure Therapy. In addition to the standard clinical treatment received by all patients at BUMC, BSWMC Temple and FH/MCW (treatment as usual), participants randomized to the intervention condition will also receive three 60-minute sessions of Brief PE. Participants in the BPE group will complete a screener and then questionnaires/interviews at 1, 2, and 6 months from Baseline.

Intervention: Brief Prolonged Exposure Therapy (Behavioral)

Outcomes

Primary Outcomes

PTSD Checklist for DSM-5 (PCL-5)

Time Frame: Baseline, 1-month, 3-month, 6-months

The PCL-5 is a 20-item, self-report measure that assesses history of traumas and PTSD symptom severity over the last month according to the DSM-5 criteria.

Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

Time Frame: Baseline, 1-month, 3-month, 6-months

The CAPS-5 is a 30-item, structured interview that assesses PTSD symptoms and makes a diagnostic determination based on the DSM-5 criteria and is considered the gold standard of PTSD assessment. Questions assess for PTSD symptoms corresponding to the 4 DSM-5 clusters of re-experiencing, avoidance, changes in mood and cognition, and arousal and hyperactivity, and includes questions on duration, impact of symptoms, distress and impact of symptoms on social and occupational functioning. The interviewer rates participant responses to symptom questions on a 5-point scale of frequency and severity, from 0 ("Absent") to 4 ("Extreme/incapacitating").

Secondary Outcomes

  • The Generalized Anxiety Disorder 7-Item (GAD-7)(Baseline, 1-month, 3-month, 6-months)
  • Patient Health Questionnaire (PHQ-9)(Baseline, 1-month, 3-month, 6-months)
  • Brief Pain Inventory-Short Form (BPI-SF)(Baseline, 1-month, 3-month, 6-months)
  • Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)(1-month, 3-month, 6-months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials